In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keio University To Research iPS Cells Of Alzheimer's Disease Patients

This article was originally published in PharmAsia News

Executive Summary

Keio University announced May 27 that it will start producing induced pluripotent stem cells from skin cells provided by patients with nervous system diseases such as Alzheimer's. The university will conduct research on the iPS cells in hopes of discovering the causes for the diseases and developing new therapeutic drugs. The team is also considering providing the iPS cells to other research facilities and companies to aid their new drug discovery effort. Besides AD, 25 other diseases are included in the research, such as Parkinson's disease, amyotrophic lateral sclerosis and retinal degeneration. (Click here for more - Japanese language

You may also be interested in...



Bayer Signs Licensing Agreement With Nagasaki University For Alzheimer’s Diagnosis Compounds

TOKYO - Bayer Schering Pharma signed a licensing agreement for worldwide development and distribution of diagnostic radioactive tracers made from compounds developed by Nagasaki University to detect Alzheimer's disease, Morio Nakayama, head of research, told PharmAsia News Sept. 17

Rethinking Alzheimer's: Mapping Out an Approval Process

Drug companies involved in Alzheimer's disease research are a little fed up with FDA. Some, like Wyeth, believe the agency should put Alzheimer's research higher up on its priority list and allow the use of surrogate endpoints for clinical trials. But FDA says that no validated surrogate exists for Alzheimer's, and until it has hard data from products in development, it is loath to recommend one. A recent reorganization of the agency's neurology group may provide an opening to press home those arguments.

Virtual Clinical Trials Find Bigger Voice As COVID-19 Forces Pharma Rethink

The use of virtual, real-time and at-home testing to provide clinical trials data has been steadily gaining the interest of the health care industry. COVID-19 has put this opportunity into sharper focus, says CNS trials technology developer Cambridge Cognition, which is now adding a voice option to its portfolio.

UsernamePublicRestriction

Register

SC142523

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel